Inhibition of 5α-reductase blocks prostate effects of testosterone without blocking anabolic effects

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 1 51-1, 2005, Pages

  Borst, Stephen E ^a,b   Lee, Jun Hak ^a   Conover, Christine F ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Body composition; Bone resorption; Dihydrotestosterone

Indexed keywords

ANDROSTANOLONE; MK 434; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; ANDROGEN; CHOLESTENONE 5ALPHA REDUCTASE; DRUG DERIVATIVE; FINASTERIDE; MK 0434;

ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; BONE; CONTROLLED STUDY; ENZYME INHIBITION; GASTROCNEMIUS MUSCLE; HORMONAL REGULATION; HORMONE ACTION; MALE; MUSCLE; MUSCLE MASS; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE; RAT; SUBCUTANEOUS FAT; TESTOSTERONE BLOOD LEVEL; URINARY EXCRETION; WEIGHT REDUCTION; ANIMAL; BLOOD; BROWN NORWAY RAT; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; METABOLISM; SKELETAL MUSCLE;

ANDROGENS; ANIMALS; BODY COMPOSITION; BONE RESORPTION; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; DRUG INTERACTIONS; FINASTERIDE; MALE; MUSCLE, SKELETAL; ORCHIECTOMY; PROSTATE; RATS; RATS, INBRED BN; TESTOSTERONE;

EID: 16644402976     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00305.2004     Document Type: Article

References (47)

1. Banerjee PP, Banerjee S, and Brown TR. Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. Endocrinology 142: 4066-4075, 2001.
2. Bartsch G, Rittmaster RS, and Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibit on in human benign prostatic hyperplasia. Eur Urol 37: 367-380, 2000.
3. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, and Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82: 407-413, 1997.
4. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, and Harman SM. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288: 2282-2292, 2002.
5. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing 33: 548-555, 2004.
6. Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, Urban RJ, and Veldhuis JD. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 87: 5649-5657, 2002.
7. Brodsky IG, Balagopal P, and Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 81: 3469-3475, 1996.
8. Brown M, Fisher JS, and Hasser EM. Gonadectomy and reduced physical activity: effects on skeletal muscle. Arch Phys Med Rehabil 82: 93-97, 2001.
9. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, and Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337: 91-95, 1997.
10. Carson JA, Lee WJ, McClung J, and Hand GA. Steroid receptor concentration in aged rat hindlimb muscle: effect of anabolic steroid administration. J Appl Physiol 93: 242-250, 2002.
11. Clague JE, Wu FC, and Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl 22: 261-265, 1999.
12. Di Salle E, Giudici D, Biagini L, Cominato C, Briatico G, and Panzeri A. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat. J Steroid Biochem Mol Biol 53: 381-385, 1995.
13. Erben RG, Eberle J, Stahr K, and Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometry study. J Bone Miner Res 15: 1085-1098, 2000.
14. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, and Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 282: E601-E607, 2002.
15. George FW. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogential tract. Endrocrinology 138: 871-877, 1997.
16. George FW and Noble JF. Androgen receptors are similar in fetal and adult rabbits. Endocrinology 115: 1451-1458, 1984.
17. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 49: 319-324, 1995.
18. Hajjar RR, Kaiser FE, and John EM. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82: 3793-3796, 1997.
19. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, and Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci 56A: M266-M272, 2001.
20. Kochakian CD. Definitions of androgens and protein anabolic steroids. Pharmacol Ther 1: 149-177, 1975.
21. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, and Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88: 204-210, 2003.
22. Magliano L, Woodhouse LJ, Bhasin S, and Storer TW. Testosterone dose-dependently increases skeletal muscle mass (SMM) in healthy men (Abstract). Med Sci Sports Exerc 36: S238, 2004.
23. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, and Waldstreicher. J. The long-term effect of specific type II 5-alpha reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 167: 2105-2108, 2002.
24. Mikuz G. Pathology of prostate cancer: old problems and new facts. Adv Clin Pathol 1: 21-24, 1997.
25. Morishima A, Grumbach MM, Simpson ER, Fisher C, and Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689-3698, 1995.
26. Parsons JK, Carter HB, Landis P, Wright EJ, Platz E, and Metter J. Higher serum free testosterone is associated with an increased risk of prostate cancer: results from the Baltimore longitudinal study on aging. Ann Meet Am Urol Soc San Francisco 2004.
27. Phillip M, Maor G, Assa S, Silbergeld A, and Segev Y. Testosterone stimulates growth of tibial epiphyseal growth plate and insulin-like growth factor-1 receptor abundance in hypophysectomized and castrated rats. Endocrine 16: 1-6, 2001.
28. Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, and Aloia JF. Effects of growth hormone and testosterone on cortical bone foundation and bone density in aged orchiectomized rats. Bone 24: 491-497, 1999.
29. Ramamani A, Aruldhas MM, and Govindarajulu P. Impact of testosterone and oestradiol on region specificity of skeletal muscle-ATP, creatine phosphokinase and myokinase in male and female Wistar rats. Acta Physiol Scand 166: 91-97, 1999.
30. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, Lazier CB, and Rowden G. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endrocrinology 136: 741-748, 1995.
31. Rogozkin V. Metabolic effects of anabolic steroid on skeletal muscle. Med Sci Sports Exerc 11: 160-163, 1977.
32. Seo SI, Kim SW, and Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl 4: 169-174, 1999.
33. Shao TC, Kong A, Marafelia P, and Cunningham GR. Effects of finasteride on the rat ventral prostate. J Androl 14: 79-86, 1993.
34. Sih R, Morely JE, Kaiser FE, Perry HM, Patrick P, and Ross C. Testosterone replacement in older hypogonadal men: a 12 month randomized, controlled trial. J Clin Endocrinol Metab 82: 1661-1667, 1997.
35. Simpson ER. Aromatase: biologic relevance of tissue-specific expression. Semin Reprod Med 22: 11-23, 2004.
36. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, and Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056-1061, 1994.
37. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Diewati A, Staley J, Santanna, Kapoor SC, Attie MF, Haddad JG, and Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endrocrinol Metab 84: 2646-2653, 1999.
38. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, and Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88: 1478-1485, 2003.
39. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl 22: 300-306, 1999.
40. Theobald HM, Roman BL, Lin TM, Ohtani S, Chen SW, and Peterson RE. 2,3,7,8-Tetrachiorodibenzo-p-dioxin inhibits luminal cell differentiation and androgen responsiveness of the ventral prostate without inhibiting prostatic 5alpha-dihydrotestosterone formation or testicular androgen production in rat offspring. Toxicol Sci 58: 324-338, 2000.
41. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, and Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17 beta-estradiol is a more effective bone-sparing and anabolic agent than 5-alpha-dihydrotestosterone. J Bone Miner Res 17: 2080-2086, 2002.
42. Vandenput L, Swinnen JV, Van Herck E, Verstuyf A, Boonen S, Bouillon R, and Vanderschueren D. The estrogen receptor ligand ICI 182,780 does not impair the bone-sparing effects of testosterone in the young orchidectomized rat model. Calcif Tissue Int 70: 170-175, 2002.
43. Vanderschueren D, Van Herck E, Suiker AM, Visser WJ, Schot LP, and Bouillon R. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology 130: 2906-2916, 1992.
44. Van Zyl CG, Noakes TD, and Lambert MI. Anabolic-androgenic steroid increases running endurance in rats. Med Sci Sports Exerc 27: 1385-1389, 1995.
45. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, and Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 85: 2839-2853, 2000.
46. Wimalawansa SM, Chapa MT, Wei JN, Westlund KN, Quast MJ, and Wimalawansa SJ. Reversal of weightlessness-induced musculoskeletal losses with androgens: quantification by MRI. J Appl Physiol 86: 1841-1846, 1999.
47. Zhou ZX, Lane MV, Kemppainen JA, French FS, and Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9: 208-218, 1995.